Oppenheimer Starts Ligand Pharma (LGND) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $303.53 -1.39%
Rating Summary:
15 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
15 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Oppenheimer initiates coverage on Ligand Pharma (NASDAQ: LGND) with a Outperform rating and a price target of $135.00.
For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.
Shares of Ligand Pharma closed at $101.35 yesterday.
You May Also Be Interested In
- Ligand to Host Investor Day on December 8, 2026
- Cantor Fitzgerald Starts Quantum Corp. (QMCO) at Overweight
- Citi Starts Yamazaki Baking Co Ltd (2212:JP) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
